Details

Autor(en) / Beteiligte

• Pölönen, Petri
• Mehtonen, Juha
• Lin, Jake
• Liuksiala, Thomas
• Häyrynen, Sergei
• Teppo, Susanna
• Mäkinen, Artturi
• Kumar, Ashwini
• Malani, Disha
• Pohjolainen, Virva
• Porkka, Kimmo
• Heckman, Caroline A
• May, Patrick
• Hautamäki, Ville
• Granberg, Kirsi J
• Lohi, Olli
• Nykter, Matti
• Heinäniemi, Merja

Titel

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

Ist Teil von

• Cancer research (Chicago, Ill.), 2019-05, Vol.79 (10), p.2466-2479

Ort / Verlag

United States

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Large collections of genome-wide data can facilitate the characterization of disease states and subtypes, permitting pan-cancer analysis of molecular phenotypes and evaluation of disease context for new therapeutic approaches. We analyzed 9,544 transcriptomes from more than 30 hematologic malignancies, normal blood cell types, and cell lines, and showed that disease types could be stratified in a data-driven manner. We then identified cluster-specific pathway activity, new biomarkers, and drug target prioritization through interrogation of drug target databases. Using known vulnerabilities and available drug screens, we highlighted the importance of integrating molecular phenotype with drug target expression for prediction of drug responsiveness. Our analysis implicated expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported as a disease-specific target in acute myeloid leukemia. Through integration with proteomics data, we characterized target protein expression for pre-B leukemia immunotherapy candidates, including DPEP1. These molecular data can be explored using our publicly available interactive resource, Hemap, for expediting therapeutic innovations in hematologic malignancies. SIGNIFICANCE: This study describes a data resource for researching derailed cellular pathways and candidate drug targets across hematologic malignancies.